Verve Therapeutics IncNASDAQ:VERV
- LAST PRICE5.0000
- TODAY'S CHANGE (%)0.0400 (0.8065%)
- Bid / Lots5.0000/ 6
- Ask / Lots5.0100/ 4
- Open / Previous Close5.0800 / 4.9600
- Day Range
- 52 Week Range
- Volume435,255
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | VERV |
|---|---|---|
| 09:32 ET | 9759 | 5.04 |
| 09:34 ET | 1309 | 5.05 |
| 09:36 ET | 1497 | 5.03 |
| 09:38 ET | 3800 | 5.03 |
| 09:39 ET | 9493 | 5.045 |
| 09:41 ET | 5027 | 5.0747 |
| 09:43 ET | 14105 | 5.08 |
| 09:45 ET | 3602 | 5.062384 |
| 09:48 ET | 2996 | 5.0325 |
| 09:50 ET | 4836 | 5.02 |
| 09:52 ET | 5322 | 4.97 |
| 09:54 ET | 4050 | 4.97 |
| 09:56 ET | 12600 | 5.01 |
| 09:57 ET | 3500 | 5 |
| 09:59 ET | 659 | 5.01 |
| 10:01 ET | 3965 | 5 |
| 10:03 ET | 1210 | 5.03 |
| 10:06 ET | 307 | 5.04 |
| 10:08 ET | 727 | 5.04 |
| 10:10 ET | 3490 | 5.07 |
| 10:12 ET | 7913 | 5.05 |
| 10:14 ET | 600 | 5.03 |
| 10:15 ET | 3402 | 5.01 |
| 10:17 ET | 4101 | 4.9972 |
| 10:19 ET | 1147 | 5 |
| 10:21 ET | 6343 | 5 |
| 10:24 ET | 1099 | 5 |
| 10:26 ET | 34920 | 5.0301 |
| 10:28 ET | 6246 | 5.075 |
| 10:30 ET | 3089 | 5.06 |
| 10:32 ET | 400 | 5.05 |
| 10:33 ET | 1050 | 5.05 |
| 10:35 ET | 3123 | 5.04 |
| 10:37 ET | 1781 | 5.05 |
| 10:39 ET | 400 | 5.06 |
| 10:42 ET | 1365 | 5.055 |
| 10:44 ET | 3057 | 5.07 |
| 10:46 ET | 2343 | 5.075 |
| 10:48 ET | 1460 | 5.09 |
| 10:50 ET | 12132 | 5.095 |
| 10:51 ET | 3489 | 5.0705 |
| 10:53 ET | 3041 | 5.05 |
| 10:55 ET | 4621 | 5.0835 |
| 10:57 ET | 2446 | 5.065 |
| 11:00 ET | 1445 | 5.07 |
| 11:02 ET | 1425 | 5.085 |
| 11:04 ET | 958 | 5.07 |
| 11:06 ET | 800 | 5.08 |
| 11:09 ET | 2526 | 5.07 |
| 11:11 ET | 1040 | 5.07 |
| 11:13 ET | 400 | 5.06 |
| 11:15 ET | 850 | 5.0701 |
| 11:18 ET | 300 | 5.075 |
| 11:20 ET | 800 | 5.09 |
| 11:22 ET | 13161 | 5.095 |
| 11:24 ET | 1260 | 5.085 |
| 11:26 ET | 1100 | 5.085 |
| 11:27 ET | 1600 | 5.065 |
| 11:29 ET | 4450 | 5.065 |
| 11:31 ET | 1550 | 5.06 |
| 11:33 ET | 3387 | 5.075 |
| 11:36 ET | 1913 | 5.075 |
| 11:38 ET | 13654 | 5.06 |
| 11:40 ET | 600 | 5.055 |
| 11:42 ET | 200 | 5.06 |
| 11:44 ET | 300 | 5.065 |
| 11:45 ET | 300 | 5.06 |
| 11:47 ET | 500 | 5.06 |
| 11:49 ET | 100 | 5.065 |
| 11:51 ET | 2220 | 5.055 |
| 11:56 ET | 403 | 5.05 |
| 11:58 ET | 494 | 5.06 |
| 12:00 ET | 518 | 5.065 |
| 12:02 ET | 500 | 5.065 |
| 12:03 ET | 2014 | 5.06 |
| 12:05 ET | 500 | 5.06 |
| 12:07 ET | 900 | 5.03 |
| 12:09 ET | 200 | 5.03 |
| 12:12 ET | 700 | 5.03 |
| 12:14 ET | 831 | 5.035 |
| 12:16 ET | 21551 | 5 |
| 12:18 ET | 1100 | 5 |
| 12:20 ET | 1223 | 5 |
| 12:21 ET | 500 | 5 |
| 12:23 ET | 1014 | 5 |
| 12:25 ET | 400 | 4.995 |
| 12:27 ET | 1400 | 5 |
| 12:30 ET | 100 | 4.995 |
| 12:32 ET | 3556 | 4.985 |
| 12:34 ET | 2694 | 4.995 |
| 12:36 ET | 500 | 4.995 |
| 12:38 ET | 1000 | 4.995 |
| 12:39 ET | 14015 | 5.025 |
| 12:41 ET | 1500 | 5.02 |
| 12:43 ET | 3171 | 5.025 |
| 12:45 ET | 382 | 5.025 |
| 12:48 ET | 1160 | 5.01 |
| 12:50 ET | 100 | 5.01 |
| 12:52 ET | 400 | 5 |
| 12:54 ET | 300 | 5.005 |
| 12:56 ET | 1063 | 5.0099 |
| 12:57 ET | 706 | 5 |
| 12:59 ET | 500 | 5 |
| 01:01 ET | 500 | 5.005 |
| 01:03 ET | 848 | 5.01 |
| 01:06 ET | 300 | 5.015 |
| 01:08 ET | 1796 | 5.005 |
| 01:10 ET | 300 | 5.005 |
| 01:12 ET | 100 | 5.005 |
| 01:14 ET | 355 | 5.005 |
| 01:15 ET | 1289 | 5.01 |
| 01:17 ET | 1925 | 5.005 |
| 01:19 ET | 200 | 5 |
| 01:21 ET | 1003 | 5.015 |
| 01:24 ET | 300 | 5.01 |
| 01:26 ET | 2126 | 5.025 |
| 01:28 ET | 100 | 5.02 |
| 01:30 ET | 3291 | 5.035 |
| 01:32 ET | 1300 | 5.035 |
| 01:33 ET | 5077 | 5.035 |
| 01:35 ET | 200 | 5.035 |
| 01:37 ET | 455 | 5.025 |
| 01:39 ET | 600 | 5.01 |
| 01:42 ET | 100 | 5.01 |
| 01:44 ET | 100 | 5 |
| 01:46 ET | 400 | 5 |
Today
Levi & Korsinsky Reminds Verve Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024 - VERV, from 1 hour ago by Dow Jones
1 hour ago by Dow JonesSHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Verve Therapeutics, Inc. - VERV, from 2 hours ago by Dow Jones
2 hours ago by Dow JonesVerve Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Verve Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024 - VERV, from 2 hours ago by Dow Jones
2 hours ago by Dow JonesVerve Therapeutics Inc Is Being Sued For Violating Securities Laws And Affected Shareholders Are Encouraged To Contact The Schall Law Firm, from 2 hours ago by Dow Jones
2 hours ago by Dow JonesLevi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 28, 2024 in Verve Therapeutics Lawsuit - VERV, from 3 hours ago by Dow Jones
3 hours ago by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Verve Therapeutics Inc | 419.7M | -1.9x | --- |
Taysha Gene Therapies Inc | 430.4M | -2.4x | --- |
Iteos Therapeutics Inc | 371.2M | -3.5x | --- |
AC Immune SA | 367.9M | -4.8x | --- |
C4 Therapeutics Inc | 432.0M | -3.2x | --- |
Tectonic Therapeutic Inc | 421.1M | -1.6x | --- |
Company Information
Verve Therapeutics, Inc. is a clinical-stage genetic medicines company. The Company is focused on developing a new approach to the care of cardiovascular disease (CVD), transforming treatment from chronic management to single-course gene editing medicines. The Company’s lead programs include VERVE-101, VERVE-102, and VERVE-201, which target genes that have been validated as targets for lowering low-density lipoprotein cholesterol (LDL-C), a root cause of atherosclerotic cardiovascular disease (ASCVD). VERVE-101 and VERVE-102 are designed to permanently turn off the PCSK9 gene in the liver and are being developed initially for heterozygous familial hypercholesterolemia (HeFH). VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed for homozygous familial hypercholesterolemia (HoFH) and for refractory hypercholesterolemia where patients still have high LDL-C despite treatment with maximally tolerated standard of care therapies.
Contact Information
- Headquarters
- 201 Brookline Avenue, Suite 601BOSTON, MA, United States 02215
- Phone
- 978-501-3026
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Burt Adelman
- President, Chief Operating Officer, General Counsel
- Andrew Ashe
- Chief Executive Officer, Director
- Sekar Kathiresan
- Chief Financial Officer
- Allison Dorval
- Chief Administrative Officer
- Joan Nickerson
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $419.7M |
|---|---|
Revenue (TTM) | $20.6M |
Shares Outstanding | 84.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-2.59 |
Book Value | $7.31 |
P/E Ratio | -1.9x |
Price/Sales (TTM) | 20.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,075.00% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
